Drug Development Market Research Reports
Nanoparticles in Biotechnology, Drug Development and Drug Delivery Market - Global Forecast, Market Share, Size, Growth and Industry Analysis, 2012 - 2018
Nanoscience or nanotechnology is the study of management of materials at molecular or atomic scale on different applications. The market for nanoparticles in drug technology holds prime share in the global pharmaceuticals market. Applications of nanotechnology can be classified into nanomedicine, chemicals and cosmetics, materials, food technology, energy, military, electronics, agriculture and others. Use of nanoparticles in pharmaceutical technology is mainly driven by growth in demand for personalized medicine. This market is classified according to applications such as biotechnology, drug development, and drug delivery. The biotechnology market is further classified according to the use of nanoparticles in fields such as research and development, cellular repair, stem cell researc
Dermatology Therapeutics Drug Development Pipeline Review, 2016
?Dermatological conditions are one of the most common types of disorders worldwide, and approximately one-third of the US population suffers from at least one active skin condition. For the past decades, the majority of the dermatology market has remained saturated with established and generic products. However, the clinical and commercial success of biologics in the treatment of psoriasis, as well as advancements in the understanding of the disease pathways of many dermatological conditions, have led to a renewed interest from pharmaceutical companies in the dermatology market, and subsequently the emergence of an innovative pipeline.
Ophthalmology Drug Development Pipeline Review, 2016
Ophthalmology disorders are associated with the eyes and visual system. If left untreated, serious long-term co-morbidities such as diabetes, and particularly blindness, can arise. Although there are a number of treatments approved in ophthalmology, there are currently no curative therapies for any of these indications.
Diabetes & Obesity Drug Development Pipeline Review, 2016
The diabetes and obesity disease cluster is currently dominated by therapeutics indicated for type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM), and the majority of the pipeline, in terms of both quantity and quality of products, is attributable to these indications. While products indicated for obesity do not currently have a large market presence, there are a large number of these products in the pipeline, with the majority in early stages of development.
Pharmacovigilance Market (Phases of Drug Development: Preclinical Studies, Clinical Trial Phase I, II, III & IV or Post Marketing Surveillance; Type of Methods: Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring, & EHR Mining; Type of Service: In-House & Contract Outsourcing) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020
Intensifying regulatory expectations, tougher inspection system, and instant need for patient reporting boost the adoption rate of pharmacovigilance among pharmaceutical companies. Rise in the prevalence of acute and chronic diseases has consequently led to an increase in the incidences of drug consumption, thus leading to growth in the number of adverse drug events and drug toxicity cases. Furthermore, safety regulations, risk of high-profile safety issues, large volume of post-market events to be reviewed along with negative media coverage have bound the pharmaceutical players to take support of various outsourcing services for drug monitoring. Two major outsourcing providers preferred by pharmaceutical manufacturers for pharmacovigilance services are namely, traditional CROs (e.g. C
Global Bioinformatics Market (By Platforms, Tools and Services and By Applications: Preventive Medicine, Molecular Medicine, Gene Therapy Drug Development and Others) - Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020
Perpetually advancing information technology (IT) and thereby expansion of application area of information technology into biotechnology and life science industry is escalating the growth of the bioinformatics market globally. Bioinformatics is widely used in recording, processing, and converting the data obtained from research and development activities related to life sciences namely, biotechnology, biopharmaceutical, pharmaceutical and agricultural fields; into computerized digital data that can be later used to expedite further research. This report covers the market analysis for various platforms, tools, and services commercially available in bioinformatics technology that helps deliver advanced information technology to ever growing life science fields such as molecul
Pediatric Drug Development - Regulatory challenges and commercial opportunities
Although pediatrics represent around two-fifths of the global population the market for pediatric medicines remains relatively small (accounting for <10% of global pharmaceutical sales). Until pediatric legislation was introduced in the US (1997) and EU (2007) there has been little incentive for the pharma industry to evaluate drugs in children due to the low medical need of chronic illnesses and the high off-label use of generic drugs (Milne & Bruss, 2008). Since the introduction of pediatric legislation there has been a substantial investment in pediatric research and the number of clinical trials performed in children has increased significantly. In the US more than 350 product labels include new pediatric information and more than 130 products have undergone a pediatric
Adaptive Licensing - A Holistic Approach to Drug Development and Regulation
Adaptive Licensing (AL) is a flexible approach to drug development and regulation, with two live pilot schemes accepted by the European Medicines Agency (EMA). The system acknowledges that levels of uncertainty will always surround innovative treatments. An initial license is granted at an earlier stage than possible under the traditional system, with less clinical information from Randomized Controlled Trials (RCTs). After the initial license is granted, the entry to market is heavily restricted, and the patient population is carefully monitored through observational studies, electronic devices and registries. Data from ongoing RCTs, and the more robust data from post-license surveillance studies are used to determine full license permission. By improving the alignment of stakeholder need
Companion Diagnostics - Streamlining drug development and advancing personalized medicine
used in screening, monitoring, diagnosing and treating patients and can allow for stratification of patients to maximize efficacy and minimize riskCompanion diagnostics can allow for a specific patient population to be identified which will ensure those patients who are most likely to respond are recruited for clinical trials and receive the therapy once the product is launched. Companion diagnostics can help to rationalize treatment decisions, with specifics such as accurate dosing, risks of adverse events and diagnostics being made possible through these tests. Through the use of companion diagnostics, the right treatment can be delivered to the right patient at the right time, delivering greater value and optimizing healthcare resource utilizationOncology has been the most active arena
Pathways to Efficient Drug Development - Advances in Modeling and Simulation Outcomes to Fuel Pipeline Productivity
Pathways to Efficient Drug Development Advances in Modeling and Simulation Outcomes to Fuel Pipeline Productivity GBI Research, the leading business intelligence provider, has released its latest research report, Pathways to Efficient Drug Development Advances in Modeling and Simulation Outcomes to Fuel Pipeline Productivity. The report examines the reasons why the pharmaceutical industry is looking for improvements in efficiency whilst acknowledging that pharmaceutical R&D remains a long and risky process. It looks in detail at precompetitive research and evaluates how the industry is pulling together to research solutions to problems that are common to all companies. The report investigates innovation in the clinical drug development arena, documenting modeling and simulation
Accelerating Drugs to Market - Despite Challenges, Adaptive Clinical Trials Reduce Drug Development Costs and Time to Market
Accelerating Drugs to Market Despite Challenges, Adaptive Clinical Trials Reduce Drug Development Costs and Time to Market GBI Researchs new report, Accelerating Drugs to Market Despite Challenges, Adaptive Clinical Trials Reduce Drug Development Costs and Time to Market, presents various tools and strategies which can accelerate a drug to the market. In this report, GBI Research has studied various hurdles at different stages of drug development that can halt a drugs development. The report provides detailed information about the need for accelerated drug development. Declining R&D productivity is highlighted as one of the major needs to be addressed. The report outlines misconceptions regarding accelerated drug development; one such major misconception is the cost of development.
Patient Perspectives - Patient Reported Outcomes Drive Drug Development, but Improving Patient Involvement Remains a Challenge
GBI Research, the leading business intelligence provider, has released its latest research, Patient Perspectives Patient Reported Outcomes Drive Drug Development, but Improving Patient Involvement Remains a Challenge. The report examines the role of patients in changing the research agenda and helping pharma companies to bring effective medicines that meet real unmet medical needs into the market place. It explores the use of patient reported outcomes in drug development, with a particular focus on their use in the regulatory setting. The report investigates whether the measures used in clinical development are relevant to patients and describes current initiatives to improve patient involvement. The final chapter explores the way in which patient involvement is changing as a result of o
Accelerating Drugs to Market - In Search of Opportunity Along the Drug Development & Approval Pathway
The commercial life of a drug and the sales trajectory achieved are dependent on a multitude of factors. One critical factor in achieving success is the ability to bring a product to market quickly to gain competitive advantages and to start recouping development costs. From product concept to market, there are a number of potential areas of opportunity for accelerating a drug through to FDA approval. Many initiatives tie to scientific and technological innovations in the research and development realm while others are tied to the regulatory pathway.The four main FDA mechanisms that can play a role in speeding drugs to market are Accelerated Approval, Priority Review, Fast Track and orphan designation. All of these were designed with the intention of facilitating development of drugs that
Emerging Market for Clinical Trials in Argentina - Major Cost Advantages over the US in Conducting Clinical Trials Will Encourage Drug Development
GBI Research has released its latest report, Emerging Market for Clinical Trials in Argentina - Major Cost Advantages over the US in Conducting Clinical Trials Will Encourage Drug Development that provides key data, information and analysis of the major trends and issues affecting the clinical trial market in Argentina. The report provides a comprehensive insight of the reasons for outsourcing clinical trials to Argentina and the key services provided by the CROs of Argentina. The report provides a detailed analysis of the Argentine market in terms of its market size. The report also discusses the factors that are driving and restraining the clinical trial market in Argentina. The report delves into the key documents required by the investigator and the sponsor before, durin
Top R&D Drug Failures - Toxicity and Serious Adverse Events in Late Stage Drug Development are the Major Causes of Drug Failure
GBI Research, leading business intelligence provider, has released its latest research report, Top R&D Drug Failures - Toxicity and Serious Adverse Events in Late Stage Drug Development are the Major Causes of Drug Failure, which provides insights into major drug failures during 20052010. The 20 drugs included in the report belong to key pharmaceutical companies and were undergoing research for a major indication. The report also includes the total expenditure of top pharmaceutical companies in R&D throughout 19962009, and an analysis of the financial loss faced by such companies when a drug fails in the late stages of development. GBI Research discovered that the economic impact of drug failure during late stage development increased in relation to the escalating cost
Lead Generation Strategies and Technologies in Drug Development - Emerging Techniques Such as Antisense Technology Will Allow Innovators to Minimize Costs
GBI Research has released its latest report, Lead Generation Strategies and Technologies in Drug Development - Emerging Techniques Such as Antisense Technology Will Allow Innovators to Minimize Costs that provides key data, information and analysis of the major trends and developments in the drug devleopment business. The report provides a comprehensive insight into key technological developments, new approaches in lead generation and various technologies developed to accelerate it.The report also provides key alliances and collaborations in the industry to minimize costs and maximize productivity. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Researchs team of industry experts. Scope